Tristar Wellness Solutions (TWSI) 10-Q 21 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	13-May-14
Document And Entity Information	'	'
Entity Registrant Name	'TRISTAR WELLNESS SOLUTIONS, INC.	'
Entity Central Index Key	'0001109153	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	23,041,713
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$138	$193
Accounts receivables, net	609	636
Prepaid expenses and other	113	178
Other receivables	1,559	1,500
Receivable from related party	2	2
Inventories, net	1,009	1,144
Total current assets	3,430	3,653
Non-current assets	'	'
Property and equipment, net	952	997
Intangible assets, net	847	867
Other non-current assets	41	41
Total non-current assets	1,840	1,905
TOTAL ASSETS	5,270	5,558
Current liabilities	'	'
Accounts payable and accrued expenses	1,366	1,321
Accounts payable and accrued expenses due to related parties	1,231	973
Current liabilities related to assets sold	1,500	1,500
Short-term notes (net of debt discount $618 and $497 as of March 31, 2014 and December 31, 2013, respectively)	1,332	714
Short-term notes - related party	3,970	3,970
Convertible notes (net of debt discount $59 and $0 as of March 31, 2014 and December 31, 2013, respectively)	389	356
Convertible notes - related party (net of debt discount $169 and $0 as of March 31, 2014 and December 31, 2013, respectively)	61	'
Deferred revenue	218	306
Derivative liability	2,038	'
Total current liabilities	12,105	9,140
Non-current Liabilities	'	'
Deferred revenue, net of current portion	'	48
Total non-current liabilities	'	48
TOTAL LIABILITIES	12,105	9,188
STOCKHOLDERS' DEFICIT	'	'
Convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 5,621,667 and 5,621,667 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	6	6
Common stock; $0.0001 par value; 50,000,000 shares authorized; 23,041,713 and 22,041,713 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively	2	2
Additional paid-in capital	19,227	18,823
Other comprehensive loss	-58	-19
Accumulated deficit	-26,012	-22,442
TOTAL STOCKHOLDERS' DEFICIT	-6,835	-3,630
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$5,270	$5,558

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
Current liabilities	'	'
Short-term notes	$618	$497
Convertible notes (net of debt discount)	59	0
Convertible notes - related party (net of debt discount)	$169	$0
STOCKHOLDERS' DEFICIT	'	'
Convertible preferred stock, par value	$0.00	$0.00
Convertible preferred stock, shares authorized	10,000,000	10,000,000
Convertible preferred stock, shares issued	5,621,667	5,621,667
Convertible preferred stock, shares outstanding	5,621,667	5,621,667
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	23,041,713	22,041,713
Common stock, shares outstanding	23,041,713	22,041,713

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements Of Operations	'	'
Sales Revenue	$1,303	$7
Cost of Goods Sold	1,038	44
Gross profit/(loss)	265	-37
Operating expenses:	'	'
General and administrative	725	1,204
Sales, marketing and development expenses	727	921
Amortization on intangible assets	20	'
Impairment of intangible assets	'	2
Total operating expenses	1,472	2,127
Loss from operations	-1,207	-2,164
Other income and (expenses)	'	'
Interest expense	-552	-9
Change in fair value of derivative liability	-1,799	'
Other	-12	'
Total other expenses	-2,363	-9
Net loss	-3,570	-2,173
Other comprehensive loss	'	'
Foreign currency translation loss	-39	'
Total comprehensive loss	($3,609)	($2,173)
Total	'	'
Loss per share	($0.16)	($0.08)
Diluted loss per share	($0.16)	($0.08)
Weighted average common shares outstanding	22,163,935	26,865,090
Diluted weighted average common shares outstanding	22,163,935	26,865,090

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities	'	'
Loss for the period from continuing operations	($3,570)	($2,173)
Adjustments to reconcile net profit/loss from continuing operations to net cash provided by operating activities:	'	'
Non-cash research and development expenses	'	921
Depreciation expenses	67	'
Change in fair value of derivative liability	1,799	'
Amortization of debt discount	278	'
Issuance of warrants for services	'	688
Intangible asset amortization	20	'
Intangible asset impairment	'	2
Imputed interest on note payable	7	9
Accounts receivables	-27	-3
Inventory	135	-15
Prepaid expenses	65	'
Accounts payable and accruals	45	49
Other receivables	-5	'
Deferred revenue	-136	'
Accounts payable and accrued expenses - related party	258	265
Net cash used in operating activities from continuing operations	-1,064	-257
Cash flow from investing activities:	'	'
Purchase of fixed assets	-22	'
Net cash used in investing activities	-22	'
Cash flow from financing activities	'	'
Proceeds from issuance of short-term notes	740	'
Proceeds from issuance of short-term convertible notes - related party	230	'
Proceeds from issuance of convertible notes	100	50
Proceeds from issuance of series D convertible preferred stock	'	250
Net cash generated from financing activities from continuing operations	1,070	300
Cumulative translation adjustment	-39	'
Net change in cash	-55	43
Cash and cash equivalent, beginning	193	11
Cash and cash equivalent, ending	138	54
Supplemental disclosure	'	'
Interest Paid	'	'
Supplemental schedule of non-cash activities	'	'
Debt discount due to convertible debentures issued with warrants	389	'
Debt discount due to embedded derivative liabilities within convertible debentures issued	239	'
Conversion of notes payable to preferred stock	'	225
Conversion of notes payable to common stock	8	32
Conversion of preferred stock to common stock	'	2
Aquisition of NorthStar Consumer Prodcuts	'	$2

The_Company

The Company	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 1. The Company	'
	TriStar Wellness Solutions, Inc. (“the Company”) was incorporated on August 28, 2000 in the state of Nevada under the name “Quadric Acquisitions”. From the date of its incorporation through April 27, 2012, the Company had several name changes and different business plans all under prior management that is no longer with the Company. On April 27, 2012, the Company underwent a change of control transaction and changed its business plan. On January 7, 2013, the Company changed its name from Biopack Environmental Solutions, Inc. to TriStar Wellness Solutions, Inc. with the State of Nevada, and such change was effected with FINRA on January 18, 2013. The Company conducts its current operations under the name TriStar Wellness Solutions, Inc. The vast majority of the Company’s operations are conducted through its wholly-owned subsidiary, HemCon Medical Technologies Inc., an Oregon corporation (“HemCon”), and involve the development, marketing and sale of HemCon’s innovative wound care products.
	Overall, the Company is focused on bringing new technologies to consumers and patients that address underserved therapeutic healthcare opportunities based on a combination of superior science, product development and market positioning worldwide. Each of the Company’s products is designed to improve health advocacy and medical outcomes through superior and proven technologies. The Company’s innovative products and technologies focus in three categories:
	·	Wound Care products focused on superior hemostasis and infection control through the exploitation of proprietary and in licensed technologies targeting a wide range of professional medical (e.g., surgery, dialysis, post-procedure recovery), trauma, military and consumer OTC (over the counter) applications reducing the total cost of care. The Company has developed FDA-approved products targeted to specific procedures within the broad professional care medical market as well as innovative products targeted to the global OTC (consumer self-care) wound care market which have received FDA clearance, CE approval and other international approvals.
	·	Women’s Health products initially focused on the unique needs during pregnancy and nursing. Longer-term the Company plans to expand the TWSI portfolio to address broader, under-met needs in women’s health. The Company markets to the maternity segment under the Beaute de Maman™ brand sold via traditional retailers and internet portals.
	·	Therapeutic Skin Care products leveraging a proprietary delivery system enabling superior dosing and consumer therapeutic benefits related to several OTC skin care needs. These technology applications are being developed for potential third party licensing or internal brand expansion.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 2. Summary of Significant Accounting Policies	'
	Basis of Presentation and Principles of Consolidation
	The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. The year-end balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). All normal recurring adjustments which are necessary for the fair presentation of the results for the interim periods are reflected herein. Operating results for the three month periods ended March 31, 2014 and 2013 are not necessarily indicative of results to be expected for a full year.
	Use of Estimates
	In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments upon issuance, and estimating the useful lives of depreciable assets and whether impairment charges may apply.
	Reclassification
	Certain reclassifications have been made to conform to prior year information to the 2014 classifications for comparative purposes.
	Stock-Based Compensation
	Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit.
	Accounting for Derivative Liabilities – Conversion Option
	The fair value of the conversion option was valued using the binomial lattice options pricing model, a “Level 3” input, based on the quoted price of common stock, volatility based on the Company’s peer group, the expected life based on the remaining contractual term of the conversion option and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the conversion options’ contractual life.
	Income Taxes
	The Company accounts for derivative instruments in accordance with ASC 815 “Derivatives and Hedging” (“ASC 815”), which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts. The Company also considers ASC 815, which provides criteria for determining whether freestanding contracts that are settled in a company’s own stock, including common stock warrants, should be designated as either an equity instrument, an asset or as a liability under ASC 815.
	Additionally, the Company evaluated the conversion feature embedded in its convertible promissory notes based on the criteria of ASC 815 to determine whether the conversion feature would be required to be bifurcated from the promissory note and accounted for separately as a derivative. Based on management’s evaluation, the embedded conversion feature meets the requirements of derivative accounting under ASC 815. The Company recorded this conversion feature at its fair value in accordance with ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). The embedded conversion feature was valued using the binomial option pricing model. Increases or decreases in the fair value of the conversion feature are included as a component of other income (expense) in the accompanying condensed consolidated statements of operations for the respective period.

Liquidity_and_Going_Concern

Liquidity and Going Concern	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 3. Liquidity and Going Concern	'
	The Company's unaudited condensed consolidated interim financial statements are prepared using accounting principles generally accepted in the United States of America (GAAP) applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has not yet established an ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. In addition, as of March 31, 2014, the Company had an accumulated deficit of $26.0 million, and had incurred a net loss for the three months ended March 31, 2014 of $3.6 million and had negative working capital of $8.7 million. Funding has been provided by related parties as well as new investors committed to make it possible to maintain, expand, and ensure the advancement of the TriStar Wellness products.
	The consolidated financial statements for the fiscal year ended December 31, 2013 states that because the Company has suffered recurring operating losses from operations, there is substantial doubt about the Company’s ability to continue as a going concern. A “going concern” opinion indicates that the consolidated financial statements have been prepared assuming the Company will continue as a going concern and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty.

Business_Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 4. Business Combinations	'
	On May 6, 2013, the Company closed the acquisition of HemCon, an Oregon corporation (“HemCon”), pursuant to the terms of an Agreement for Purchase and Sale of Stock entered into by and between us and HemCon (the “Agreement”). The Agreement was entered into as part of HemCon’s Fifth Amended Plan of Reorganization in its bankruptcy proceeding (United States Bankruptcy Court, District of Oregon, Case No. 12-32652-elp11) and was approved by the Court as part of HemCon’s approved Plan of Reorganization. Under the Agreement, the Company purchased 100 shares of HemCon’s common stock, representing 100% of HemCon’s then-outstanding voting securities, in exchange for approximately $3.1 million (the “Purchase Price”). The Purchase Price was paid to the Court and the Trustee of the bankruptcy proceeding to be distributed to HemCon’s creditors in accordance with the Plan of Reorganization.
	The acquisition has been accounted for under the acquisition method of accounting. Accordingly, the assets and liabilities of the acquired entity were recorded at their estimated fair values at the date of the acquisition. The operating results for HemCon have been included in the Company's consolidated financial statements since the acquisition date.
	The purchase price allocation is based on estimates of fair value as follows (in thousands):
	Accounts receivables	$	653
	Other receivables		1,500
	Inventory		1,410
	Other current assets		23
	Prepaid expenses		156
	Fixed assets		1,193
	Accounts payable and accrued expenses		(341	)
	Current liabilities related to assets held for sale		(1,500	)
	Deferred revenue		(882	)
	Patents		336
	Customer list		198
	Trade name		266
	Non-compete agreement		127
	Total acquisition cost allocated	$	3,139
	Management assigned fair values to the identifiable intangible assets through a combination of the relief from royalty method and the multi-period excess earnings method.
	The useful lives of the acquired intangibles are as follows:
		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16
	Intangible asset amortization expense for the three months ended March 31, 2014 and March 31, 2013 was $20 and $0, respectively.
	The following unaudited pro forma financial information presents results as if the acquisition of HemCon had occurred on January 1, 2014 and January 1, 2013 (in thousands):
		Three Months Ended March 31 ,
	(Unaudited)	2014			2013
	Total revenue	$	1,303			$	1,290
	Net loss from continuing operations	$	-3,565			$	(4,493	)

Inventories

Inventories	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 5. Inventories	'
	Inventories, net consist of the following at March 31, 2014 and December 31, 2013 (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	349	$	318
	Work in Progress		212		251
	Finished Goods		448		575
		$	1,009	$	1,144
	Reserve for obsolescence was approximately $279 for three months ended March 31, 2014.

Property_and_Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 6. Property and Equipment	'
	Property and equipment consist of the following at March 31, 2014 and December 31, 2013 (in thousands):
		Estimate Useful Life (Years)		31-Mar-14			31-Dec-13
	Manufacturing Equipment		10-Jul	$	623		$	623
	Leasehold Improvements		7		520			520
	Office Furniture and Equipment		7-Mar		32			32
	Computer Equipment and Software		5-Jan		12			12
	Construction in Progress				6			6
					1,193			1,193
	Less: Accumulated Depreciation, amortization and impairments				(241	)		(196	)
				$	952		$	997
	Deprecation expense was approximately $67 for the three months ended March 31, 2014 and $0 for the three months ended March 31, 2103.

Loans_Payable

Loans Payable	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 7. Loans Payable	'
		March 31,		December 31,
		2014		2013
	Short-term notes (net of debt discount $618 and $497 as March 31, 2014 and December 31, 2013, respectively)	$	1,332	$	714
	Short-term notes - related party		3,970		3,970
		$	5,302	$	4,684
	Convertible notes (net of debt discount $59 and $0 as of March 31, 2014 and December 31, 2013, respectively)	$	389	$	356
	Convertible notes – related party (net of debt discount $169 and $0 as of March 31, 2014 and December 31, 2013, respectively)		61		-
		$	5,752	$	5,040
	Promissory Notes
	1st Quarter 2014 Activity
	On January 15, 2014, the Company issued a convertible promissory note (“Note”) to a third party, in the principal amount of $100. The note has an interest rate of 24% per annum, simple interest and is due on or before July 15, 2014. In connection with this promissory note, the Company issued warrants to purchase 1,000,000 shares of our common stock at an exercise price $1.32 per share, which was the fair market value of our common stock on the date of issuance. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.68%, volatility – 111.11%, expected term – 5 years, expected dividends– N/A. The debt discounts related to the warrants are being amortized over a 0.5 year period (through maturity) on a straight-line basis. The Company recorded a debt discount related to the warrants of $91 by crediting additional paid in capital. Amortization expense on the debt discount was $41. At any time after February 1, 2014, or in the event of default, the holder may choose to convert the balance due from this Note into sufficient number of common shares of the Company, to constitute 1% of the total number of fully diluted and, by doing so, accept the payment of shares as payment in full for the outstanding balance. The Note contain an embedded conversion feature that the Company has determined is a derivative requiring bifurcation in accordance with the provisions of ASC 815. The embedded conversion feature of the Notes was valued at approximately $2,386 using the binomial option pricing model at January 15, 2014. The fair value of the conversion feature was determined using the binomial option pricing model with the following assumptions: risk free interest rate – 0.06%, volatility – 111.11%, expected term – 0.5 years, expected dividends– N/A.
	During the first quarter of 2014 the Company issued a promissory note to a third party, in the principal amount of $740. The note has an interest rate of 21% per annum, simple interest and is due on or before November 30, 2014. In connection with this promissory note, the Company issued warrants to purchase 850,000 shares of our common stock at an exercise price between $0.75 and $1.32 per share, which was the fair market value of our common stock on the date of issuance. The relative fair value of the warrants compared to the debt was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying consolidated balance sheet as of March 31, 2014. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.56%, volatility – 100.10%, expected term – 4 years, expected dividends– N/A. The debt discounts related to the warrants are being amortized over a 0.8 year period (through maturity) on a straight-line basis. The Company recorded a debt discount related to the warrants of $298 by crediting additional paid in capital. Amortization expense on the debt discount was $176 for the three months ended March 31, 2014.
	During the first quarter of 2014 the Company issued convertible promissory notes (“Notes”) to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $230. The note has an interest rate of 24% per annum, simple interest and is due on or before August 11, 2014. No warrants were issued in connection with the promissory note. The Notes contain an embedded conversion feature that the Company has determined is a derivative requiring bifurcation in accordance with the provisions of ASC 815. At any time after February 1, 2014, or in the event of default, the holder may choose to convert the balance due from this Note into sufficient number of common shares of the Company, to constitute 1% of the total number of fully diluted and, by doing so, accept the payment of shares as payment in full for the outstanding balance. The embedded conversion feature of the Notes was valued at approximately $1,483 using the binomial option pricing model at February 11, 2014. The fair value of the conversion feature was determined using the binomial option pricing model with the following assumptions: risk free interest rate – 0.10%, volatility – 92%, expected term – 0.5 years, expected dividends– N/A. Amortization expense on the debt discount was $61 for the three months ended March 31, 2014.
	During the first quarter of 2014, two third parties partially converted their notes payable, in accordance with the original terms of the notes, with an aggregate principal amount of $8,000 into 1,000,000 common shares.
	The Company recorded imputed interest on convertible debentures and interest expense of $7 and $9 for the three months ended March 31, 2014 and 2013 respectively, based upon a market interest rate of 8% and accrued interest based on the stated rate of 0.5%.

Stockholders_Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 8. Stockholders' Equity	'
	Diluted Shares
	There were 405,000 shares of Series A, 1,000,000 shares of Series B and no shares of Series C outstanding as of March 31, 2014. Each share of Preferred D is convertible into twenty five shares of common stock. Convertible preferred stock was considered anti-dilutive for the three months ended March 31, 2014 and 2013, due to net losses. As of March 31, 2014, there are 4,216,667 Series D Convertible Preferred Shares which are convertible into 105,416,675 of common shares. All Series D Convertible Preferred Stock voting rights are on an “as converted to common stock” basis. Dividends are not mandatory. If declared by the Board Series D Preferred Stock shall have preference over common stock and equal to other series of preferred stock. As of March 31, 2014, there are 8,182,600 warrants which are convertible into one share of common stock with a weighted average exercise price of $1.62. In addition, convertible debt of $682 as of March 31, 2014 is convertible into 47,789,867 shares of the Company’s common stock.
	The Company has determined that common stock equivalents in excess of available authorized common shares are not derivative instruments due to the fact that an increase in authorized shares is within the Company’s control.
	Note Conversions
	All note conversions were within the original conversion terms and therefore no gain or loss was recorded on these conversions.
	During the first quarter of 2014, two third parties partially converted their notes payable, in accordance with the original terms of the notes, with an aggregate principal amount of $8,000 into 1,000,000 common shares.
	Detachable Warrants
	During the first quarter of 2014, the Company issued Promissory Notes containing 1,850,000 detachable Warrants. The relative fair value of the detachable Warrants compared to the debt of approximately $389 was recorded as a component of stockholders’ equity with the offset recorded as a discount on the promissory notes and included as a component of promissory notes in the accompanying condensed consolidated balance sheet as of March 31, 2014. The fair value of the warrants was determined using the Black-Scholes model with the following assumptions: risk free interest rate – 1.46% - 1.68%, volatility – 99.58 – 111.11%, expected term – 4 to 5 years, expected dividends– N/A. The debt discount related to the warrants are being amortized over a six to ten month period (through maturity) on a straight-line basis.

Related_Party_Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 9. Related Party Transactions	'
	Consulting Agreements
	On January 6, 2014 the Company entered into a revised consulting agreement with Chord Advisors, LLC ("Chord"). David Horin, the Company's Chief Financial Officer has a significant equity partnership stake in Chord. Currently the agreement is on a month to month basis. The Company has agreed to pay Chord a monthly consulting fee of approximately $13 for Mr. Horin's services and services of his firm and 50,000 warrants upon the consummation of a financing transaction in excess of $2 million with an exercise price equal to the exercise price of such warrants in a financing transaction. The Company incurred $38 and $38 for the three months ended March 31, 2014 and 2013, respectively, and has an accounts payable balance related to this agreement of $120 as of March 31, 2014.
	Accounts Payable and Accrued Expenses
	As of March 31, 2014 the Company owed Daystar $50, James Barickman $3, John Linderman 16, Highpeak $2, Ingber $6, Northstar $271 and Rivercoach $72. The Company owed accrued compensation of $70,500 to related party officers as of March 31, 2014.
	Related Party Notes
	During the first quarter of 2014 the Company issued convertible promissory notes (“Notes”) to DayStar Funding, LP, a Texas limited partnership and a party controlled by Frederick A. Voight one of our officers and directors, in the principal amount of $230. The note has an interest rate of 24% per annum, simple interest and is due on or before August 11, 2014. No warrants were issued in connection with the promissory note. The Notes contain an embedded conversion feature that the Company has determined is a derivative requiring bifurcation in accordance with the provisions of ASC 815. The embedded conversion feature of the Notes was valued at approximately $1,483 using the binomial option pricing model at February 11, 2014. The fair value of the conversion feature was determined using the binomial option pricing model with the following assumptions: risk free interest rate – 0.10%, volatility – 92%, expected term – .05 years, expected dividends– N/A. Amortization expense on the debt discount was $61 for the three months ended March 31, 2014.
	As of March 31, 2014, the Company owed to Daystar Funding, LP $3,970 and accrued interest of $621. As of March 31, 2014, the company owed John Linderman and James Barickman $24 and $8 of accrued interest.

Intangible_Assets_Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 10. Intangible Assets, Net	'
	On May 6, 2013, the Company closed the acquisition of HemCon Medical Technologies Inc., an Oregon corporation (“HemCon”), pursuant to the terms of an Agreement for Purchase and Sale of Stock entered into by and between us and HemCon (the “Agreement”). The Agreement was entered into as part of HemCon’s Fifth Amended Plan of Reorganization in its bankruptcy proceeding (United States Bankruptcy Court, District of Oregon, Case No. 12-32652-elp11) and was approved by the Court as part of HemCon’s approved Plan of Reorganization. Under the Agreement, the Company purchased 100 shares of HemCon’s common stock, representing 100% of HemCon’s then-outstanding voting securities, in exchange for $3,139 in cash (the “Purchase Price”). The Purchase Price was paid to the Court and the Trustee of the bankruptcy proceeding to be distributed to HemCon’s creditors in accordance with the Plan of Reorganization.
	For the three months ended March 31, 2014, intangible assets consisted primarily of patents, customer lists, non-compete arrangements and a trade name. Patents, customer lists, non-compete arrangements and a trade name acquired in business combinations under the purchase method of accounting are recorded at fair value net of accumulated amortization since the acquisition date. The intangible assets are amortized over their estimated useful life which is 4 to 16 years.
	The amortization expense for the three months ended March 31, 2014 and March 31, 2013 was $20 and $0, respectively.
						Amortized as of		Balance as of
	Description	Life in Years		Price		31-Mar-14		31-Mar-14
	Patents		12	$	336		25	$	311
	Customer list		14		198		13	$	185
	Trade name		16		266		14	$	252
	Non-compete agreement		4		127		28	$	99
				$	927		80	$	847

Litigation

Litigation	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 11. Litigation	'
	The Company recognizes a liability for a contingency when it is probable that liability has been incurred and when the amount of loss can be reasonably estimated. When a range of probable loss can be estimated, the Company accrues the most likely amount of such loss, and if such amount is not determinable, then the Company accrues the minimum of the range of probable loss. As of March 31, 2014, there was no litigation against the Company and therefore the litigation accrual was zero.

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 12. Fair Value Measurements	'
	The Company has adopted the provisions of ASC 820 which defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. ASC 820 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820 provides guidance on how to measure certain financial assets and financial liabilities at fair value. The requirement to measure an asset as liability at fair value is determined under the U.S. GAAP.
	Certain of the Company’s assets and liabilities are considered to be financial instruments and are required to be measured at fair value in the consolidated balance sheets. Certain of these financial instruments, including cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, short-term debt and deferred revenue are measured at cost, which approximates fair value due to the short-term maturity of these instruments. Derivative liabilities are measured at fair value.
	The Company measures fair value basis based on the following key objectives:
		•	Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date;
		•	A three-level hierarchy (“Valuation Hierarchy”) which prioritizes the use of observable pricing data (Level 1 and Level 2 inputs as defined below) over unobservable pricing data (Level 3 inputs as defined below) is used in measuring value; and
		•	The Company’s creditworthiness is considered when measuring the fair value of liabilities.
	The valuation hierarchy used in measuring fair value is defined as follows:
		•	Level 1 inputs are observed inputs such as quoted prices for identical instruments inactive markets;
		•	Level 2 inputs are inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments inactive markets or quoted prices for identical or similar instruments in markets that are not active; and
		•	Level 3 inputs are unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs are unobservable. Level 3 requires significant management judgment or estimation.
	All items measures at fair value are required to be classified and disclosed as a Level 1, 2 or 3 asset or liability based on the inputs used to measure for value of an asset or liability in its entirety. An asset or liability classified as Level 1 is measured by quoted prices in active markets for identical instruments. An asset or liability classified as Level 2 is measured using significant observable inputs and an asset or liability classified as Level 3 is measured using significant unobservable inputs.
	The following table classifies the Company’s liabilities measured at fair value on a recurring basis (primarily reflecting an increase in stock price per share) into the fair value as of March 31, 2014 and December 31, 2013 (in thousands):
	Description		Level 1			Level 2		Level 3
	Derivative liability- conversion options		$	-		$	-	$	2,038
	The following table represents our assets and liabilities by level measured at fair value on a recurring basis at December 31, 2013:
	Description		Level 1		Level 2	Level 3
			None		None	None
	There were no transfers between Level 1, 2 or 3 during the three months ended March 31, 2014.
	The following table presents changes in Level 3 liabilities measured at fair value from the period ended December 31, 2013 through March 31, 2014. Both observable and unobservable inputs are used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.
	Balance – December 31, 2013		$	-
	Discount related to embedded conversion feature 1			239
	Change in fair value of derivative liability-conversion option			1,799
	Balance – March 31, 2014		$	2,038
	1 The Notes contain an embedded conversion feature that the Company has determined is a derivative requiring bifurcation in accordance with the provisions of ASC 815.

Subsequent_Events

Subsequent Events	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
Note 13. Subsequent Events	'
	Stock Options for Services
	During the second quarter of 2014, the Company issued 50,000 warrants to Hemcon employees with an exercise price of $0.38 and a four year term. Each option is exercisable into one share of common stock.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2014
Summary Of Significant Accounting Policies Policies	'
Basis of Presentation and Principles of Consolidation	'
	The accompanying unaudited condensed consolidated interim financial statements should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2013. The year-end balance sheet data was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America (“GAAP”). All normal recurring adjustments which are necessary for the fair presentation of the results for the interim periods are reflected herein. Operating results for the three month periods ended March 31, 2014 and 2013 are not necessarily indicative of results to be expected for a full year.
Use of Estimates	'
	In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include valuing equity securities in share-based payment arrangements, estimating the fair value of equity instruments upon issuance, and estimating the useful lives of depreciable assets and whether impairment charges may apply.
Reclassification	'
	Certain reclassifications have been made to conform to prior year information to the 2014 classifications for comparative purposes.
Stock-Based Compensation	'
	Compensation expense for all stock-based awards is measured on the grant date based on the fair value of the award and is recognized as an expense, on a straight-line basis, over the employee's requisite service period (generally the vesting period of the equity award). The fair value of each option award is estimated on the grant date using a Black-Scholes option valuation model. Stock-based compensation expense is recognized only for those awards that are expected to vest using an estimated forfeiture rate. We estimate pre-vesting option forfeitures at the time of grant and reflect the impact of estimated pre-vesting option forfeitures in compensation expense recognized. For options and warrants issued to non-employees, the Company recognizes stock compensation costs utilizing the fair value methodology over the related period of benefit.
Accounting for Derivative Liabilities - Conversion Option	'
	The fair value of the conversion option was valued using the binomial lattice options pricing model, a “Level 3” input, based on the quoted price of common stock, volatility based on the Company’s peer group, the expected life based on the remaining contractual term of the conversion option and the risk free interest rate based on the implied yield available on U.S. Treasury Securities with a maturity equivalent to the conversion options’ contractual life.
Income Taxes	'
	The Company accounts for derivative instruments in accordance with ASC 815 “Derivatives and Hedging” (“ASC 815”), which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts. The Company also considers ASC 815, which provides criteria for determining whether freestanding contracts that are settled in a company’s own stock, including common stock warrants, should be designated as either an equity instrument, an asset or as a liability under ASC 815.
	Additionally, the Company evaluated the conversion feature embedded in its convertible promissory notes based on the criteria of ASC 815 to determine whether the conversion feature would be required to be bifurcated from the promissory note and accounted for separately as a derivative. Based on management’s evaluation, the embedded conversion feature meets the requirements of derivative accounting under ASC 815. The Company recorded this conversion feature at its fair value in accordance with ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”). The embedded conversion feature was valued using the binomial option pricing model. Increases or decreases in the fair value of the conversion feature are included as a component of other income (expense) in the accompanying condensed consolidated statements of operations for the respective period.

Business_Combinations_Tables

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2014
Business Combinations Tables	'
Estimates of fair value	'
	The purchase price allocation is based on estimates of fair value as follows (in thousands):
	Accounts receivables	$	653
	Other receivables		1,500
	Inventory		1,410
	Other current assets		23
	Prepaid expenses		156
	Fixed assets		1,193
	Accounts payable and accrued expenses		(341	)
	Current liabilities related to assets held for sale		(1,500	)
	Deferred revenue		(882	)
	Patents		336
	Customer list		198
	Trade name		266
	Non-compete agreement		127
	Total acquisition cost allocated	$	3,139
Useful lives	'
	The useful lives of the acquired intangibles are as follows:
		Useful Lives
	Patents		12
	Customer lists		14
	Non-compete arrangements		4
	Trade name		16
Acquisition financial information	'
	The following unaudited pro forma financial information presents results as if the acquisition of HemCon had occurred on January 1, 2014 and January 1, 2013 (in thousands):
		Three Months Ended March 31 ,
	(Unaudited)	2014			2013
	Total revenue	$	1,303			$	1,290
	Net loss from continuing operations	$	-3,565			$	(4,493	)

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2014
Inventories Tables	'
Inventories	'
	Inventories, net consist of the following at March 31, 2014 and December 31, 2013 (in thousands):
		March 31,		December 31,
		2014		2013
	Raw materials	$	349	$	318
	Work in Progress		212		251
	Finished Goods		448		575
		$	1,009	$	1,144

Property_and_Equipment_Tables

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2014
Property And Equipment Tables	'
Property and Equipment	'
	Property and equipment consist of the following at March 31, 2014 and December 31, 2013 (in thousands):
		Estimate Useful Life (Years)		31-Mar-14			31-Dec-13
	Manufacturing Equipment		10-Jul	$	623		$	623
	Leasehold Improvements		7		520			520
	Office Furniture and Equipment		7-Mar		32			32
	Computer Equipment and Software		5-Jan		12			12
	Construction in Progress				6			6
					1,193			1,193
	Less: Accumulated Depreciation, amortization and impairments				(241	)		(196	)
				$	952		$	997

Loans_Payable_Tables

Loans Payable (Tables)	3 Months Ended
	Mar. 31, 2014
Loans Payable Tables	'
Schedule of Short term loans	'
		March 31,		December 31,
		2014		2013
	Short-term notes (net of debt discount $618 and $497 as March 31, 2014 and December 31, 2013, respectively)	$	1,332	$	714
	Short-term notes - related party		3,970		3,970
		$	5,302	$	4,684
Schedule of Long term loans	'
	Convertible notes (net of debt discount $59 and $0 as of March 31, 2014 and December 31, 2013, respectively)	$	389	$	356
	Convertible notes – related party (net of debt discount $169 and $0 as of March 31, 2014 and December 31, 2013, respectively)		61		-
		$	5,752	$	5,040

Intangible_Assets_Net_Tables

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2014
Intangible Assets Net Tables	'
Schedule of intangible assets	'
	The amortization expense for the three months ended March 31, 2014 and March 31, 2013 was $20 and $0, respectively.
						Amortized as of		Balance as of
	Description	Life in Years		Price		31-Mar-14		31-Mar-14
	Patents		12	$	336		25	$	311
	Customer list		14		198		13	$	185
	Trade name		16		266		14	$	252
	Non-compete agreement		4		127		28	$	99
				$	927		80	$	847

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Measurements Tables	'
Assets and liabilities by level measured at fair value on a recurring basis	'
	The following table classifies the Company’s liabilities measured at fair value on a recurring basis (primarily reflecting an increase in stock price per share) into the fair value as of March 31, 2014 and December 31, 2013 (in thousands):
	Description	Level 1			Level 2		Level 3
	Derivative liability- conversion options	$	-		$	-	$	2,038
	The following table represents our assets and liabilities by level measured at fair value on a recurring basis at December 31, 2013:
	Description	Level 1		Level 2	Level 3
		None		None	None
Changes in Level 3 liabilities measured at fair value	'
	Balance – December 31, 2013	$	-
	Discount related to embedded conversion feature 1		239
	Change in fair value of derivative liability-conversion option		1,799
	Balance – March 31, 2014	$	2,038

Liquidity_and_Going_Concern_De

Liquidity and Going Concern (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Liquidity And Going Concern Details Narrative	'
Accumulated deficit	$26,000
Working capital deficit	8,700
Net loss	($3,570)

Business_Combinations_Details

Business Combinations (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Business Combinations Details	'
Accounts receivables	$653
Other receivables	1,500
Inventory	1,410
Other current assets	23
Prepaid expenses	156
Fixed assets	1,193
Accounts payable and accrued expenses	-341
Current liabilities related to assets held for sale	-1,500
Deferred revenue	-882
Patents	336
Customer list	198
Trade name	266
Non-compete agreement	127
Total acquisition cost allocated	$3,139

Business_Combinations_Details_

Business Combinations (Details 2) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Business Combinations Details 2	'	'
Total revenue	$1,303	$1,290
Net loss	($3,565)	($4,493)

Business_Combinations_Details_1

Business Combinations (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Business Combinations Details Narrative	'	'
Additional interest expense	$20	$0

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventories Details	'	'
Raw Materials	$349	$318
Work In Progress	212	251
Finished Goods	448	575
Inventories net	$1,009	$1,144

Inventories_Details_Narrative

Inventories (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Inventories Details Narrative	'
Reserve for obsolescence	$279

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Property and Equipment, Gross	$1,193	$1,193
Less: Accumulated Depreciation, amortization and impairments	-241	-196
Property and Equipment, Net	952	997
Manufacturing Equipment [Member]	'	'
Property and Equipment, Gross	623	623
Manufacturing Equipment [Member] | Minimum [Member]	'	'
Estimates Useful Life	'7 years	'
Manufacturing Equipment [Member] | Maximum [Member]	'	'
Estimates Useful Life	'10 years	'
Leasehold Improvements [Member]	'	'
Estimates Useful Life	'7 years	'
Property and Equipment, Gross	520	520
Office Furniture and Equipment [Member]	'	'
Property and Equipment, Gross	32	32
Office Furniture and Equipment [Member] | Minimum [Member]	'	'
Estimates Useful Life	'3 years	'
Office Furniture and Equipment [Member] | Maximum [Member]	'	'
Estimates Useful Life	'7 years	'
Computer Equipment and Software [Member]	'	'
Property and Equipment, Gross	12	12
Computer Equipment and Software [Member] | Minimum [Member]	'	'
Estimates Useful Life	'1 year	'
Computer Equipment and Software [Member] | Maximum [Member]	'	'
Estimates Useful Life	'5 years	'
Construction in Progress [Member]	'	'
Property and Equipment, Gross	$6	$6

Property_and_Equipment_Details1

Property and Equipment (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Property And Equipment Details Narrative	'	'
Depreciation expense	$67	$0

Loans_Payable_Details

Loans Payable (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Loans Payable Details	'	'
Short term notes	$1,332	$714
Short term notes - related party	3,970	3,970
Loans Payable	$5,302	$4,684

Loans_Payable_Details_1

Loans Payable (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Long term loans	'	'
Convertible notes	$389	$356
Convertible notes - related party	61	'
Convertible notes, Total	$5,752	$356

Loans_Payable_Details_Narrativ

Loans Payable (Details Narrative) (USD $)	3 Months Ended		3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2013
			DayStar Funding, LP [Member]	DayStar Funding, LP [Member]
Principal amount	$740	$230	$230	'
Interest rate	21.00%	'	24.00%	'
Maturity Date	'due on or before November 30, 2014	'	'due on or before August 11, 2014	'
Issued warrants to purchase	850,000	'	'	'
Common stock exercise price	$0.75	'	'	'
common stock exercise price 1	$1.32	'	'	'
Risk free interest rate	1.56%	'	0.10%	'
Expected volatility rate	100.10%	'	92.00%	'
Expected term	'4 years	'	'6 months	'
Expected dividend	'	'	'	'
Debt discount related to warrants amortized maturity period	'9 months 18 days	'	'	'
Aggregate principal amount notes payable	8,000	'	'	'
common shares related to notes payable	1,000,000	'	'	'
Amortization expense on the debt discount	176	'	61	'
Debt discount related to the warrants	298	'	'	'
Market interest rate	'	'	8.00%	'
Accrued interest based on the stated rate	'	'	0.50%	'
Convertible debentures and interest expense	'	'	$7	$9

Stockholders_Equity_Details_Na

Stockholders' Equity (Details Narrative) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014
Convertible warrants	8,182,600
Weighted average exercise price	$1.62
Convertible debt	$682
Convertible shares of Company common stock	47,789,867
Aggregate principal amount notes payable	8,000
common shares related to notes payable	1,000,000
Risk free interest rate	1.56%
Volatility	100.10%
Expected term	'4 years
Debt discount related to warrants amortized maturity period	'9 months 18 days
Series D Convertible Preferred Stock	'
Preferred Shares convertible into number of common shares	4,216,667
Converted common shares	105,416,675
Series A Preferred Stock [Member]	'
Preffered shares	405,000
Series B Preferred Stock [Member]	'
Preffered shares	1,000,000
Series C Preferred Stock [Member]	'
Preffered shares	0
Detachable Warrants One [Member]	'
Relative fair value of the detachable Warrants	$389
Issued detachable Warrants	1,850,000
Detachable Warrants One [Member] | Minimum [Member]	'
Risk free interest rate	1.46%
Volatility	99.58%
Expected term	'4 years
Expected dividend	'
Debt discount related to warrants amortized maturity period	'6 months
Detachable Warrants One [Member] | Maximum [Member]	'
Risk free interest rate	16.80%
Volatility	111.11%
Expected term	'5 years
Expected dividend	'
Debt discount related to warrants amortized maturity period	'10 months

Related_Party_Transactions_Det

Related Party Transactions (Details Narrative) (USD $)	3 Months Ended					3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Dec. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
			DayStar Funding, LP [Member]	John Linderman [Member]	James Barickman [Member]	Highpeak, LLC [Member]	Rivercoach Partners LP [Member]	NorthStar Consumer Products, LLC [Member]	NorthStar Consumer Products, LLC [Member]	Chord Advisors, LLC [Member]
Consulting fee incurred	'	'	'	'	'	$20	$20	$38	$38	'
Accounts payable balance	'	'	'	'	'	10	72	271	'	113
Reimbursable expenses	120	'	'	'	'	'	'	'	'	'
Additional paid in capital	'	'	50	16	3	2	'	'	'	'
Principal amount	$740	$230	$230	'	'	'	'	'	'	'
Interest rate per annum	'	24.00%	'	'	'	'	'	'	'	'

Intangible_Assets_Net_Details

Intangible Assets, Net (Details) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Intangible assets, Price	$927
Intangible assets, Amortized	80
Intangible asset, balance	847
Patents [Member]	'
Intangible assets, Life in Years	'12 years
Intangible assets, Price	336
Intangible assets, Amortized	25
Intangible asset, balance	311
Customer Lists [Member]	'
Intangible assets, Life in Years	'14 years
Intangible assets, Price	198
Intangible assets, Amortized	13
Intangible asset, balance	185
Patents [Member]	'
Intangible assets, Life in Years	'16 years
Intangible assets, Price	266
Intangible assets, Amortized	14
Intangible asset, balance	252
Non-compete Agreements [Member]	'
Intangible assets, Life in Years	'4 years
Intangible assets, Price	127
Intangible assets, Amortized	28
Intangible asset, balance	$99

Intangible_Assets_Net_Details_

Intangible Assets, Net (Details Narrative) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Intangible Assets Net Details Narrative	'	'
Intangible assets amortized over estimated useful life	'4 to 16 years	'
Amortization expense	$20	$0

Litigation_Details_Narrative

Litigation (Details Narrative) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Litigation Details Narrative	'	'
Litigation accrual	$0	$0

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivative liability- conversion options	'	'
Level 1 [Member]	'	'
Derivative liability- conversion options	'	'
Level 2 [Member]	'	'
Derivative liability- conversion options	'	'
Level 3 [Member]	'	'
Derivative liability- conversion options	$2,038	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets and liabilities measured at fair value on recurring basis	'	'
Level 1 [Member]	'	'
Assets and liabilities measured at fair value on recurring basis	'	'
Level 2 [Member]	'	'
Assets and liabilities measured at fair value on recurring basis	'	'
Level 3 [Member]	'	'
Assets and liabilities measured at fair value on recurring basis	$2,038	'

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (USD $)	Mar. 31, 2014
In Thousands, unless otherwise specified
Fair Value Measurements Details 2	'
Balance - December 31, 2013	'
Discount related to embedded conversion feature 1	239
Change in fair value of derivative liability-conversion option	1,799
Balance - March 31, 2014	$2,038